Most human cancers are characterized by genomic instability. Changes associated with such may result in altered expression of numerous genes. The sequence information available in the public databases can be used to identify transcripts differentially expressed in cancers. Determining cancer-related genes that are commonly deregulated in different tumor types may facilitate identification of targets for cancer diagnoses and therapeutic treatments. Using a data-mining tool named Digital Differential Display (DDD) from the UniGene database at the NCBI web site, gene expression levels of ten different tumor types and their counterpart normal tissues were analyzed. Unigenes which showed transcriptional regulation in more than five tumor types with ≧2-fold differences from normal tissues were identified. The expression data of selected Unigenes were subjected to clustering analysis. 127 commonly up-regulated genes and 92 commonly down-regulated genes were identified. Clustering analysis using these genes showed that most tumor types can be clustered into a separate branch from most normal tissues. Nineteen genes that have been shown to be involved in carcinogenesis by experimental evidence were also identified. Present computational analyses revealed 219 candidate cancer-related genes that are commonly deregulated in ten human tumor types which may contribute to the progress of carcinogenesis.   

Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM: Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. J Cell Biol 158:165–174 (2002).
Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245–248 (1999).
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57–70 (2000).
Ito Y, Yoshida H, Nakano K, Kobayashi K, Yokozawa T, Hirai K, Matsuzuka F, Matsuura N, Kuma K, Miyauchi A: Expression of p57/Kip2 protein in normal and neoplastic thyroid tissues. Int J Mol Med 9:373–376 (2002).
Kikuchi T, Toyota M, Itoh F, Suzuki H, Obata T, Yamamoto H, Kakiuchi H, Kusano M, Issa JP, Tokino T, Imai K: Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene 21:2741–2749 (2002).
Leerkes MR, Caballero OL, Mackay A, Torloni H, O’Hare MJ, Simpson AJ, de Souza SJ: In silico comparison of the transcriptome derived from purified normal breast cells and breast tumor cell lines reveals candidate upregulated genes in breast tumor cells. Genomics 79:257–265 (2002).
Mahtabifard A, Merritt RE, Yamada RE, Crystal RG, Korst RJ: In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies. J Thorac Cardiovasc Surg 126:28–38 (2003).
Mason MD, Davies G, Jiang WG: Cell adhesion molecules and adhesion abnormalities in prostate cancer. Crit Rev Oncol Hematol 41:11–28 (2002).
Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ: p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650–662 (1995).
Mei R, Galipeau PC, Prass C, Berno A, Ghandour G, Patil N, Wolff RK, Chee MS, Reid BJ, Lochhart DJ: Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays. Genome Res 10:1126–1137 (2000).
Miyagishi D, Ohno-Matsui K, Amagasa T, Morita I: Regulation of the expression of pigment epithelium-derived factor, an anti-angiogenic factor in human oral squamous cell carcinoma cell lines. Cancer Lett 196:77–85 (2003).
Modugno M, Tagliabue E, Ardini E, Berno V, Galmozzi E, De Bortoli M, Castronovo V, Menard S: p53-dependent downregulation of metastasis-associated laminin receptor. Oncogene 21:7478–7487 (2002).
Peterson LE: CLUSFAVOR 5.0: hierarchical cluster and principal-component analysis of microarray-based transcriptional profiles. Genome Biol 3:SOFTWARE0002 (2002).
Ricky WJ, Astrid AR, Scott WL: Apoptosis: A link between cancer genetics and chemotherapy. Cell 108:153–164 (2002).
Scheurle D, DeYoung MP, Binninger DM, Page H, Jahanzeb M, Narayanan R: Cancer gene discovery using digital differential display. Cancer Res 60:4037–4043 (2000).
Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J: The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 123:513–522 (1993).
Schuler GD, Boguski MS, Stewart EA, Stein LD, Gyapay G, Rice K, White RE, Rodriguez-Tome P, et al: A gene map of the human genome. Science 274:540–546 (1996).
Shi Y, Zhai H, Wang X, Wu H, Ning X, Han Y, Zhang D, Xiao B, Wu K, Fan D: Multidrug-resistance-associated protein MGr1-Ag is identical to the human 37-kDa laminin receptor precursor. Cell Mol Life Sci 59:1577–1583 (2002).
Sporn MB: The war on cancer. Lancet 347:1377–1381 (1996).
Stanton JL, Macgregor AB, Green DPL: Using expressed sequence tag databases to identify ovarian genes of interest. Mol Cell Endocrin 191:11–14 (2002).
Takita J, Ishii M, Tsutsumi S, Tanaka Y, Kata K, Toyoda Y, Hanada R, Yamamoto K, Hayashi Y, Aburatani H: Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma. Genes Chrom Cancer 40:120–132 (2004).
Tang K, Nie D, Cai Y, Honn KV: The beta4 integrin subunit rescues A431 cells from apoptosis through a PI3K/Akt kinase signaling pathway. Biochem Biophys Res Commun 264:127–132 (1999).
Tatusov RL, Koonin EV, Lipman DJ: A genomic perspective on protein families. Science 278:631–637 (1997).
Toyama T, Iwase H, Yamashita H, Hara Y, Omoto Y, Sugiura H, Zhang Z, Fujii Y: Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett 189:97–102 (2003).
Zada AA, Singh SM, Reddy VA, Elsasser A, Meisel A, Haferlach T, Tenen DG, Hiddemann W, Behre G: Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation. Oncogene 22:2296–2308 (2003).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.